This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The datasets analyzed during the current study are available from the corresponding author on reasonable request.
References
Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016;122:2941–51. https://doi.org/10.1002/cncr.30130
Dalle IA, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019;94:1388–95. https://doi.org/10.1002/ajh.25648
Hirschbühl K, Labopin M, Houhou M, Gabellier L, Labussière-Wallet H, Lioure B, et al. Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2021;56:1190–9. https://doi.org/10.1038/s41409-020-01173-x
Aldoss I, Shah BD, Park JH, Muffly L, Logan AC, Brown P, et al. Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. 2023;98:666–80. https://doi.org/10.1002/ajh.26853
Bazarbachi A, Labopin M, Aljurf M, Niittyvuopio R, Balsat M, Blaise D, et al. 20-year steady increase in survival of adult patients with relapsed Philadelphia-positive acute lymphoblastic leukemia post allogeneic hematopoietic cell transplantation. Clin Cancer Res. 2022;28:1004–12. https://doi.org/10.1158/1078-0432.ccr-21-2675
Qin Y, Chen S, Jiang B, Jiang Q, Jiang H, Li J, et al. Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol. 2011;90:47–52. https://doi.org/10.1007/s00277-010-1039-57
Chen H, Liu KY, Xu LP, Chen YH, Han W, Zhang XH, et al. Haploidentical Hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of Philadelphia Chromosome positive acute lymphoblastic leukemia. Biol Blood Marrow Transpl 2015;21:1110e1116.
Chen H, Xu LP, Zhang XH, Wang Y, Chen YH, Yan CH, et al. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation. Leuk Res. 2022;121:106930. https://doi.org/10.1016/j.leukres.2022.106930
Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Zhao XY, et al. Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Hematol Oncol 2012;5:29.
Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, et al. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 2017;31:2587–93. https://doi.org/10.1038/leu.2017.145
Kim R, Calandon Y, Rousellot P, Cayuela JM, Huguet F, Balsat M, et al. Significance of measurable residual disease in adult Philadelphia chromosome–positive ALL: A GRAAPH-2014 Study. J Clin Oncol. 2024;42:3140–50.
Acknowledgements
This work was supported by the National Key Research and Development Program of China (No. 2022YFA1103300), Major Program of the National Natural Science Foundation of China (No. 82293630), Beijing Municipal Science & Technology Commission (No. Z211100002921071), and Peking University Medicine Fund for world’s leading discipline or discipline cluster development (No.71003Y3035). We would like to thank Editage (www.editage.com) for language editing.
Author information
Authors and Affiliations
Contributions
HC designed the study, interpreted the data, and wrote the manuscript; L-PX, X-HZ, YW, Y-HC, Y-FC, YC, X-DM, Y-QS, Y-YZ, C-HY, WH, Y-JC conducted the research and contributed to writing the manuscript; Y-ZQ performed BCR-ABL RQ-PCR, direct sequencing for BCR-ABL kinase domain mutation assays; X-JH was the principal investigator, designed the study, interpreted the data, and wrote the manuscript. All the authors have read and approved the final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
The study was reviewed and approved by the Ethics Committee of Peking University People’s Hospital and was conducted in accordance with the Declaration of Helsinki. Patients or their legal guardians had provided written informed consent for the data collection and any subsequent analysis of data before the transplantation procedure.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Chen, H., Xu, LP., Zhang, XH. et al. Long-term survival in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation: a single-center experience. Bone Marrow Transplant (2025). https://doi.org/10.1038/s41409-025-02698-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41409-025-02698-9
